Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DD6AZ5
|
|||
| Drug Name |
BNC-101
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Metastatic colorectal cancer [ICD-11: 2B91; ICD-10: C19] | Phase 1 | [1] | |
| Company |
Bionomics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leucine-rich repeat-containing GPCR 5 (LGR5) | Target Info | Inhibitor | [2] |
| Reactome | Regulation of FZD by ubiquitination | |||
| WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02726334) A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Bionomics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.